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Abstract—Competing risks occur frequently in the analysis of survival data. A competing risk is an event whose occurrence 
precludes the occurrence of the primary event of interest. In a study examining time to death attributable to cardiovascular 
causes, death attributable to noncardiovascular causes is a competing risk. When estimating the crude incidence of 
outcomes, analysts should use the cumulative incidence function, rather than the complement of the Kaplan-Meier 
survival function. The use of the Kaplan-Meier survival function results in estimates of incidence that are biased upward, 
regardless of whether the competing events are independent of one another. When fitting regression models in the presence 
of competing risks, researchers can choose from 2 different families of models: modeling the effect of covariates on the 
cause-specific hazard of the outcome or modeling the effect of covariates on the cumulative incidence function. The 
former allows one to estimate the effect of the covariates on the rate of occurrence of the outcome in those subjects who 
are currently event free. The latter allows one to estimate the effect of covariates on the absolute risk of the outcome 
over time. The former family of models may be better suited for addressing etiologic questions, whereas the latter model 
may be better suited for estimating a patient’s clinical prognosis. We illustrate the application of these methods by 
examining cause-specific mortality in patients hospitalized with heart failure. Statistical software code in both R and SAS 
is provided. (Circulation. 2016;133:601–609. DOI: 10.1161/CIRCULATIONAHA.115.017719.)
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Introduction to the Analysis of Survival Data 
in the Presence of Competing Risks
Peter C. Austin, PhD; Douglas S. Lee, MD, PhD; Jason P. Fine, PhD
Cardiovascular research often focuses on outcomes that are defined as the time to the occurrence of an outcome 
of interest. Common examples include time to death attrib-
utable to any cause, time to cause-specific death (eg, death 
attributable to cardiovascular causes), and time to the first of 
any major adverse cardiac event (MACE; eg, cardiovascular 
death or acute myocardial infarction). Less common examples 
include time to shock or appropriate therapy in patients under-
going implantable cardiac defibrillator implantation or time 
to heart transplant in patients on a transplant waiting list. We 
use the term survival data to refer to data in which the out-
come variable denotes the time to the occurrence of the event 
of interest. Others refer to such data as time-to-event data or 
event history data. The Kaplan-Meier method for estimating 
survival functions and the Cox proportional hazards model for 
estimating the effects of covariates on the hazard of the occur-
rence of the event are commonly used statistical methods for 
the analysis of survival data. We refer the interested reader 
elsewhere for further background on these methods and others 
for the analysis of survival data.1–7
A distinctive feature of survival data is the concept of 
censoring. If the event of interest is death, then the time of 
the event is censored for those subjects who are still alive at 
the end of the study. This means that the statistical analysis 
must proceed without knowledge of when the subject will die. 
All that is known about the timing of their death is that it is 
after the time at which the study ended. More generally, in a 
follow-up study, subjects who drop out are censored, because 
they are typically lost to follow-up and the time of the occur-
rence of their event is unknown. The event time is unobserved 
for censored subjects: all that is known is that their event 
time occurred after the time at which they were censored. An 
implicit concept in the definition of censoring is that, if the 
study had been prolonged (or if subjects had not dropped out), 
602  Circulation  February 9, 2016
eventually the outcome of interest would have been observed 
to occur for all subjects. Conventional statistical methods for 
the analysis of survival data make the important assumption of 
independent or noninformative censoring.1,3,6 This means that, 
at a given point in time, subjects who remain under follow-
up have the same future risk for the occurrence of the event 
as those subjects no longer being followed (either because of 
censoring or study dropout), as if losses to follow-up were 
random and thus noninformative.
A competing risk is an event whose occurrence precludes 
the occurrence of the primary event of interest. For instance, 
in a study in which the primary outcome was time to death 
attributable to a cardiovascular cause, death attributable to a 
noncardiovascular cause serves as a competing event. A sub-
ject who dies of cancer is no longer at risk of death attributable 
to cardiovascular causes. Regardless of how long the duration 
of follow-up is extended, a subject will not be observed to die 
of cardiovascular causes once he or she has died of cancer. 
Competing risks can also be present in studies in which the 
different event types include nonfatal outcomes when one is 
interested in which event type occurred first. Thus, one may 
have a study with 3 types of events: diagnosis of heart disease, 
diagnosis of cancer, and death. Each type of event serves as a 
competing risk, because a diagnosis of cancer before a diag-
nosis of heart disease or of death precludes either of these lat-
ter 2 events from happening first.
Conventional statistical methods for the analysis of sur-
vival data assume that competing risks are absent. Two com-
peting risks are said to be independent if information about 
a subject’s risk of experiencing 1 type of event provides no 
information about the subject’s risk of experiencing the other 
type of event. The methods that we describe in this tutorial 
apply equally to settings in which competing risks are inde-
pendent of one another and to settings in which competing 
risks are not independent of one another. In biomedical appli-
cations, the biology often suggests at least some dependence 
between competing risks, which in many cases may be quite 
strong. Accordingly, independent competing risks may be 
relatively rare in biomedical applications.
When analyzing survival data in which competing risks 
are present, analysts frequently censor subjects when a com-
peting event occurs. Thus, when the outcome is time to death 
attributable to cardiovascular causes, an analyst may consider 
a subject as censored once that subject dies of noncardiovas-
cular causes. However, censoring subjects at the time of death 
attributable to noncardiovascular causes may be problematic. 
First, it may violate the assumption of noninformative cen-
soring: it may be unreasonable to assume that subjects who 
died of noncardiovascular causes (and were thus treated as 
censored) can be represented by those subjects who remained 
alive and had not yet died of any cause. Second, even when 
the competing events are independent, censoring subjects at 
the time of the occurrence of a competing event may lead 
to incorrect conclusions because the event probability being 
estimated is interpreted as occurring in a setting where the 
censoring (eg, the competing events) does not occur. In the 
cardiovascular example described above, this corresponds to 
a setting where death from noncardiovascular causes is not a 
possibility. Although such probabilities may be of theoretical 
interest, they are of questionable relevance in many practi-
cal applications, and generally lead to overestimation of the 
cumulative incidence of an event in the presence of the com-
peting events.8–11
The objective of this tutorial is to introduce readers to sta-
tistical methods for the analysis of survival data that account 
for competing risks. This article is structured as follows. In 
Statistical Methods for the Analysis of Survival Data in the 
Presence of Competing Risks, we introduce statistical con-
cepts and methods for the analysis of survival data in the 
presence of competing events. In Case Study, we illustrate 
the application and interpretation of these methods by using 
a data set of subjects hospitalized with heart failure. Finally, 
in Discussion, we summarize our tutorial and place it in the 
context of the existing literature.
Statistical Methods for the Analysis of Survival 
Data in the Presence of Competing Risks
In this section we compare and contrast conventional statisti-
cal methods for survival analysis with statistical methods that 
account for competing risks.
Estimating Crude Incidence
We assume that there is a well-defined baseline time in the 
cohort and that T denotes the time from baseline time until 
the occurrence of the event of interest. In the absence of 
competing risks, the survival function, S(t), describes the 
distribution of event times: S t T t( ) Pr( )= > . One minus the 
survival function (ie, the complement of the survival func-
tion), F t S t T t( ) ( ) Pr( )= − = ≤1  describes the incidence of the 
event over the duration of follow-up. Two key properties of 
the survival function are that S(0) = 1 (ie, at the beginning 
of the study, the event has not yet occurred for any subjects) 
and lim ( )
t
S t
→∞
= 0 (ie, eventually the event of interest occurs for 
all subjects). In practice, the latter assumption may not be 
required, because the probability of the event over a restricted 
follow-up period may be <1.
Estimating the incidence of an event as a function of 
follow-up time provides important information on the abso-
lute risk of an event. In the absence of competing risks, the 
Kaplan-Meier estimate of the survival function is frequently 
used for estimating the survival function. One minus the 
Kaplan-Meier estimate of the survival function provides an 
estimate of the cumulative incidence of events over time. In 
the case study that follows, we examine the incidence of car-
diovascular death in patients hospitalized with heart failure. 
When the complement of the Kaplan-Meier function was 
used, the estimated incidence of cardiovascular death within 
5 years of hospital admission was 43.0%. However, using the 
Kaplan-Meier estimate of the survival function to estimate the 
incidence function in the presence of competing risks gener-
ally results in upward biases in the estimation of the incidence 
function.9,10,12 In particular, the sum of the Kaplan-Meier esti-
mates of the incidence of each individual outcome will exceed 
the Kaplan-Meier estimate of the incidence of the compos-
ite outcome defined as any of the event types. Even when the 
competing events are independent, the Kaplan-Meier estima-
tor yields biases in the probability of the event of interest. The 
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problem here is that the Kaplan-Meier estimator estimates the 
probability of the event of interest in the absence of compet-
ing risks, which is generally larger than that in the presence of 
competing risks. Furthermore, the hypothetical population in 
which competing risks do not exist may not be the population 
of greatest interest for clinical and/or policy making,13 as in 
the cardiovascular setting where noncardiovascular death may 
be an important consideration.
The Cumulative Incidence Function (CIF), as distinct from 
1 – S(t), allows for estimation of the incidence of the occur-
rence of an event while taking competing risk into account. 
This allows one to estimate incidence in a population where 
all competing events must be accounted for in clinical decision 
making. The cumulative incidence function for the kth cause 
is defined as: CIFk t T t D k( ) Pr( , )= ≤ = , where D is a variable 
denoting the type of event that occurred. A key point is that, 
in the competing risks setting, only 1 event type can occur, 
such that the occurrence of 1 event precludes the subsequent 
occurrence of other event types. The function CIFk t( ) denotes 
the probability of experiencing the kth event before time t and 
before the occurrence of a different type of event. The CIF 
has the desirable property that the sum of the CIF estimates 
of the incidence of each of the individual outcomes will equal 
the CIF estimates of the incidence of the composite outcome 
consisting of all of the competing events. Unlike the survival 
function in the absence of competing risks, CIFk t( )will not 
necessarily approach unity as time becomes large, because of 
the occurrence of competing events that preclude the occur-
rence of events of type k. In the case study that follows, when 
using the CIF, the estimated incidence of cardiovascular death 
within 5 years of hospital admission was 36.8%. This esti-
mate was 6.2% lower than the estimate obtained using the 
complement of the Kaplan-Meier function. This illustrates the 
upward bias that can be observed when naively using Kaplan-
Meier estimate in the presence of competing risks.
Hazard Function Regression
A key concept in survival analysis is that of the hazard func-
tion. In the absence of competing risks, the hazard function is 
defined as
λ( ) lim ( | ) .t t T t t T t
tt
=
≤ < + ≥
→∆
∆
∆0
Prob
The hazard function, which is a function of time, describes 
the instantaneous rate of occurrence of the event of interest in 
subjects who are still at risk of the event. In a setting in which 
the outcome was all-cause mortality, the hazard function at 
a given point in time would describe the instantaneous rate 
of death in subjects who were alive at that point in time. The 
Cox proportional hazards regression model relates the hazard 
function to a set of covariates.2 In the absence of competing 
events, the Cox proportional hazards regression model can be 
written as log( ( )) log( ( ))λ λt t= +0 Xβ , where λ0( )t denotes the 
baseline hazard function (ie, the hazard function for a subject 
whose covariates are all set equal to zero), X denotes a set 
of explanatory variables, and β denotes the associated regres-
sion parameters. The model can also be written in multiplica-
tive format: λ λ( ) ( )exp( )t t= 0 Xβ . The Cox model relates the 
covariates to the hazard function of the outcome of interest 
(and not directly to the survival times themselves). The covari-
ates have a relative effect on the hazard function because of 
the use of the logarithmic transformation. The regression 
coefficients are interpreted as log-hazard ratios. The hazard 
ratio is equal to the exponential of the associated regression 
coefficient. The hazard ratio denotes the relative change in 
the hazard function associated with a 1-unit increase in the 
predictor variable. Although the regression coefficients from 
the Cox model describe the relative effect of the covariates 
on the hazard of the occurrence of the outcome, the follow-
ing relationship also holds in the absence of competing risks: 
S t S t X( ) ( )exp( )= 0 β , where S t( ) denotes the survival function for 
an individual whose set of covariates is equal to X, and S t0( )
denotes the baseline survival function (ie, the survival func-
tion for a subject whose covariates are all equal to zero). Thus, 
the relative effect of a given covariate on the hazard of the 
outcome is equal to the relative effect of that covariate on the 
logarithm of the survival function. Therefore, in the absence 
of competing risks, making inferences about the effect of a 
covariate on the hazard function permits one to make equiva-
lent inferences about the effect of that covariate on prognosis 
or survival. This direct correspondence between the hazard 
function and incidence in the absence of competing risks has 
allowed authors to be imprecise in their language when inter-
preting the fitted Cox regression model. Authors have been 
able to conclude that a given risk factor or variable increased 
the risk of an event, without specifying whether risk denoted 
the hazard of an event (ie, the rate of the occurrence of the 
event in those still at risk of the event) or the incidence of the 
event (ie, the probability of the occurrence of the event).
Competing risks implies that a subject can experience one 
of a set of different events or outcomes. In this case, 2 differ-
ent types of hazard functions are of interest: the cause-specific 
hazard function and the subdistribution hazard function. The 
former function9,10 is defined as 
λkcs tt
t T t t D k T t
t
( ) lim ( , | ) .= ≤ < + = ≥
→∆
∆
∆0
Prob
The cause-specific hazard function denotes the instanta-
neous rate of occurrence of the kth event in subjects who are 
currently event free (ie, in subjects who have not yet experi-
enced any of the different types of events). If one were con-
sidering 2 types of events, death attributable to cardiovascular 
causes and death attributable to noncardiovascular causes, 
then the cause-specific hazard of cardiovascular death denotes 
the instantaneous rate of cardiovascular death in subjects who 
have not yet experienced either event (ie, in subjects who are 
still alive). The subdistribution hazard function, introduced by 
Fine and Gray,9,10,14 is defined as
λksd tt
t T t t D k T t T t K k
t
( ) lim ( , | ( )) .= < ≤ + = > ∪ < ∩ ≠
→∆
∆
∆0
Prob
It denotes the instantaneous risk of failure from the kth 
event in subjects who have not yet experienced an event of 
type k. Note that this risk set includes those who are currently 
event free as well as those who have previously experienced a 
competing event. This differs from the risk set for the cause-
specific hazard function, which only includes those who are 
currently event free. Using the same example as above, the 
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subdistribution hazard of cardiovascular death denotes the 
instantaneous rate of cardiovascular death in subjects who are 
still alive (ie, who have not yet experienced either event) or 
who have previously died of noncardiovascular causes. There 
is a distinct cause-specific hazard function for each of the dis-
tinct types of events and a distinct subdistribution hazard func-
tion for each of the distinct types of events.
In settings in which competing risks are present, 2 dif-
ferent hazard regression models are available: modeling the 
cause-specific hazard and modeling the subdistribution hazard 
function. Both models account for competing risks, but do so 
by modeling the effect of covariates on different hazard func-
tions. Consequently, each model has its unique interpretation. 
We refer to these 2 models as cause-specific hazard models and 
subdistribution hazard models. The second model has also been 
described as a CIF regression model. The latter name makes 
explicit the link between the subdistribution hazard and the 
effect on the incidence of an event. That is, one may directly pre-
dict the cumulative incidence for an event of interest using the 
usual relationship between the hazard and the incidence function 
under the proportional hazards model. Thus, the subdistribution 
hazard model allows one to estimate the effect of covariates on 
the cumulative incidence function for the event of interest.
Lau et al suggest that cause-specific hazard models are 
“better suited for studying the etiology of diseases, where 
the [subdistribution hazard model] has use in predicting an 
individual’s risk.”9(p245) Similarly, Koller and colleagues15 sug-
gested that subdistribution hazard-based methods are prefer-
able when the focus is on estimating actual risks and prognosis. 
This echoes the previous distinction made between interpreta-
tion of the incidence rate and the hazard rate. Furthermore, the 
subdistribution hazard may be of greater interest if one is inter-
ested in the overall impact of covariates on the incidence of the 
outcome of interest, even when predictions of incidence are not 
of direct interest. These arguments suggest that subdistribution 
hazards models should be used for developing clinical predic-
tion models and risk-scoring systems for survival outcomes, 
whereas cause-specific hazard models may be more appropri-
ate for addressing epidemiological questions of etiology. The 
rationale for this suggestion is that the cause-specific hazard 
function denotes the instantaneous rate of the primary outcome 
in those subjects who are currently event free. Thus, a regres-
sion coefficient from a cause-specific hazard model can be 
interpreted as the relative effect of the corresponding covariate 
on the relative increase in the rate of the occurrence of the pri-
mary event in subjects who are currently event free. In contrast 
to this, clinical prediction models and risk-scoring systems are 
interested in estimating the absolute incidence of the event of 
interest. As the subdistribution hazard model allows one to 
model directly the effect of covariates on the incidence of the 
primary event after accounting for competing events, it lends 
itself naturally to risk prediction. The need to carefully consider 
which model is appropriate to address the research question is 
illustrated in the case study below, in which the effect of cancer 
is shown to have a different effect on the subdistribution hazard 
of cardiac death in comparison with its effect on the cause-
specific hazard of cardiac death. Cancer was associated with 
a substantial decrease in the incidence of cardiac death (sub-
distribution hazard ratio, 0.82), whereas it had no association 
with the rate of cardiac death in subjects who were still alive 
(cause-specific hazard ratio, 0.96). An important point to grasp 
is that in the presence of competing risks, the simple 1-cause 
Cox model is inadequate. Instead, researchers must be aware 
of the different hazard functions that are available in the pres-
ence of competing risks and decide which one is best suited to 
their research objectives.
Statistical Software for Competing Risks Analyses
CIFs can be estimated in R using the cuminc function in the 
cmprsk package; in SAS, one can use the %CIF macro; Stata 
permits estimation of the CIF using the stcurve function. Note 
that in SAS/STAT 13.1, %CIF is an autocall macro, and thus 
does not need to be loaded manually by the analyst.
Cause-specific hazard models can be fit in any statistical 
software package that permits estimation of the conventional 
Cox proportional hazards model. One simply treats those sub-
jects who experience a competing event as being censored at 
the time of the occurrence of the competing event. In R, one 
can use the coxph function in the survival package, in SAS, 
one can use PROC PHREG, and in Stata, one can use the 
stcox function.
Subdistribution hazard models can be fit in R by using the 
crr function in the cmprsk package. In SAS, PROC PHREG 
permits estimation of subdistribution hazard models through 
the use of the 'eventcode' option in the model statement (in 
SAS/STAT version 13.1). In Stata, the stcrreg function permits 
estimation of subdistribution hazard regression models.
In the case study below, we used the R (version 3.1.2) 
statistical programming language and the cmprsk package 
(version 2.2–6) for all of the statistical analyses. R code for 
estimating the CIFs, the subdistribution hazard models and 
the cause-specific hazard models is described in Appendix 
A in the online-only Data Supplement. SAS code for fitting 
these functions and models is described in Appendix B in the 
online-only Data Supplement.
Case Study
Data Sources
The Enhanced Feedback for Effective Cardiac Treatment 
(EFFECT) Study was designed to assess the effect of pub-
lic reporting of hospital performance on the quality of care 
provided to patients with cardiovascular disease in Ontario, 
Canada.16 We obtained detailed clinical data by retrospective 
chart review on patients hospitalized with heart failure (HF) 
between April 1, 1999 and March 31, 2001 (phase 1) and 
between April 1, 2004 and March 31, 2005 (phase 2) at 103 
hospitals in Ontario, Canada. Trained cardiovascular nurse 
abstractors collected data on patient demographics, vital signs 
and physical examination at presentation, medical history, 
and results of laboratory tests. These data sets were linked by 
using unique, encoded identifiers and they were analyzed at 
the Institute for Clinical Evaluative Sciences.
We considered 11 baseline covariates, which make up 
the EFFECT-HF mortality prediction model: age, systolic 
blood pressure on admission, respiratory rate on admission, 
low sodium serum concentration (<136 mEq/L), low serum 
hemoglobin (<10.0 g/dL), serum urea nitrogen, presence 
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of cerebrovascular disease, presence of dementia, chronic 
obstructive pulmonary disease, hepatic cirrhosis, and cancer. 
The initial sample consisted of 18 284 patients hospitalized 
with HF. We excluded 255 subjects who were on dialysis for 
end-stage renal failure, because the EFFECT-HF mortality 
prediction model was not intended for use in these subjects. 
We excluded an additional 1792 subjects with missing data on 
continuous covariates in the EFFECT-HF mortality prediction 
model. This left 16 237 patients for analysis (8521 patients in 
phase 1 and 7716 patients in phase 2).
Subjects were linked by using an encoded version of the 
patient’s Ontario health insurance number to the Vital Statistics 
database maintained by the Ontario Office of the Registrar 
General. This database contains information on date of death 
and cause of death for residents of Ontario. Each subject was 
followed for 5 years from the date of hospital admission for the 
occurrence of death. For those subjects who died within 5 years 
of discharge, the cause of death was noted in the Vital Statistics 
database. We categorized cause of death as cardiovascular ver-
sus noncardiovascular: 10 215 (63%) patients died during the 5 
years of follow-up. Of these, 5970 (58%) died of cardiovascular 
causes, and 4245 (42%) died of noncardiovascular causes.
Descriptive Statistical Analyses
Descriptive statistics for patients in the study sample are reported 
in Table 1. We summarized continuous variables by using medi-
ans and the 25th and 75th percentiles, whereas dichotomous 
variables were summarized by using frequencies and percent-
ages. Patients who died of cardiovascular causes tended to 
be older and to have lower systolic blood pressure, increased 
serum urea nitrogen, a higher prevalence of cerebrovascular 
diseases, a lower prevalence of cancer, chronic obstructive pul-
monary disease, and low serum hemoglobin in comparison with 
patients who died of noncardiovascular causes.
Crude Incidence of Cardiovascular and 
Noncardiovascular Death
Cumulative incidences of cardiovascular and noncardiovascu-
lar death in the overall sample are described in Figure 1, along 
with the incidence of the composite outcome of all-cause mor-
tality. The cumulative incidence of all-cause mortality is equal 
to the sum of the cumulative incidences of the 2 cause-specific 
mortalities. Although the cumulative incidence of cardiovas-
cular death exceeded that of noncardiovascular death at each 
point in time, the incidence of noncardiovascular death was 
not negligible in this population. A figure similar to Figure 1 
should be presented to estimate cumulative incidence in the 
presence of competing risk.13
In Figure 2, 3 additional curves have been added to the 
cumulative incidence functions described in Figure 1: esti-
mates of the incidence of each of the 2 outcomes derived 
from the complement of the Kaplan-Meier estimate of the 
survival function, along with the sum of the incidence of 
each outcome derived from the 2 Kaplan-Meier survival 
functions. Two observations warrant merit. First, as antici-
pated, the Kaplan-Meier estimate of incidence of each of 
the 2 outcomes is larger than the corresponding estimate 
derived from the CIF. The overestimates of incidence 
when using the Kaplan-Meier estimates are moderately 
large for both cardiovascular death and noncardiovascular 
death. Second, the sum of the 2 Kaplan-Meier estimates of 
incidence is greater than the estimate of incidence of the 
composite outcome of all-cause mortality. The estimates 
described in Figure 2 illustrate the incorrect estimates of 
cumulative incidence that can arise when an analyst naïvely 
uses the Kaplan-Meier survival function to estimate cumu-
lative incidence.
Hazard Models for Cardiovascular Death
We fit cause-specific and subdistribution hazard models for 
both cardiovascular death and noncardiovascular death. For 
each of the 2 causes of death, we regressed the hazard of death 
on the 11 covariates described above. The estimated hazard 
ratios, along with their associated confidence intervals, are 
reported in Table 2. It is important to remember that the 2 
models have different interpretations when interpreting the 
regression coefficients from the cause-specific hazard models 
and the subdistribution hazard models.
Table 1. Baseline Characteristics of Patients in the EFFECT-HF Sample
Variable
EFFECT-HF Sample 
(N=16 237)
Cardiac Death 
(N=5970)
Noncardiac Death 
(N=4245)
Age 78 (70–84) 81 (74–87) 79 (73–85)
Respiratory rate at admission, breaths/min 24 (20–28) 24 (20–28) 24 (20–28)
Systolic blood pressure at admission, mm Hg 145 (124–169) 140 (120–162) 144 (124–168)
Serum urea nitrogen, mg/dL 24 (17–34) 27 (19–39) 25 (18–38)
Cancer 1889 (12) 631 (11) 764 (18)
Cirrhosis 120 (1) 44 (1) 46 (1)
Cerebrovascular disease 2827 (17) 1267 (21) 784 (18)
Dementia 1457 (9) 743 (12) 510 (12)
Chronic obstructive pulmonary disease 4066 (25) 1499 (25) 1316 (31)
Low serum hemoglobin (<10.0 g/dL) 2068 (113) 781 (13) 773 (18)
Low sodium serum concentration (<136 mEq/L) 3457 (21) 1419 (224) 998 (24)
Cells reporting patient characteristics contain either n (%) for dichotomous variables or median (25th 
percentile–75th percentile [Q1–Q3]) for continuous variables. EFFECT-HF indicates Enhanced Feedback for 
Effective Cardiac Treatment Heart Failure Study.
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A 10-year increase in age increased the relative incidence 
of cardiac death by 42%, whereas it increased the relative inci-
dence of noncardiac death by 14%. Similarly, a 10-year increase 
in age increased the cause-specific hazard of cardiac death by 
52%, whereas it increased the cause-specific hazard of noncar-
diac death by 31%. Thus, age had a more pronounced effect on 
both the incidence and cause-specific hazard of cardiac mortal-
ity than on noncardiac mortality. Furthermore, age had a more 
pronounced effect on the cause-specific hazard of a given out-
come than it did on the incidence of the same outcome.
The presence of cancer had a small and nonsignificant 
effect on the cause-specific hazard of cardiac death, whereas 
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it increased the cause-specific hazard of noncardiac death by 
85%. This illustrates how the apparent reduction in the abso-
lute risk of cardiac death from cancer may be explained via the 
effect of cancer on noncardiac death.17
In examining the estimated hazard ratios for the differ-
ent outcomes and different types of hazard models, one notes 
that some variables have a qualitatively similar effect on the 
incidence of cardiac death as on the incidence of noncardiac 
death. However, other variables have a qualitatively different 
effect on the incidence of cardiac death in comparison with 
the effect on the incidence of noncardiac death. Furthermore, 
some variables have a qualitatively similar effect on the inci-
dence of a given type of death as on the cause-specific haz-
ard for the same type of death. As described elsewhere, the 
interpretation of these results requires careful consideration 
of the effects of variables on competing causes of death.17 
As an example, a strong and opposing effect of a variable on 
the cause-specific hazard of a competing event may lead to 
an indirect effect on the cumulative incidence of the event 
of interest. To be concrete, a strong prognostic factor for the 
cause-specific hazard for cardiovascular death might lead to 
an apparent decrease in the cumulative incidence for noncar-
diovascular death when such factor has no effect on the cause-
specific hazard for noncardiovascular death. This indirect 
effect of the prognostic factor for cardiovascular death occurs 
because noncardiovascular death cannot occur in those who 
die of cardiovascular causes and hence have a decreased risk 
for that event.
Discussion
The analysis of survival data plays a key role in cardiovascular 
research. Competing risks are prevalent in much of cardio-
vascular research. Failure to account correctly for competing 
events can result in adverse consequences, including overes-
timation of the probability of the occurrence of the event and 
mis-estimation of the magnitude of relative effects of covari-
ates on the incidence of the outcome. Koller et al15 found that 
competing risks were present in a large majority of studies 
published in a sample of high-impact journals. This sug-
gests that it is crucial that investigators be aware of appropri-
ate methods to account for competing risks when analyzing 
survival data. We have provided a brief, nontechnical, intro-
duction to statistical methods to account for the presence of 
competing risks. We refer the interested reader to introductions 
and reviews of differing levels of statistical depth.8–13,15,17–21 We 
summarize our recommendations in Table 3.
When estimating crude incidence of the outcome of 
interest, it is inappropriate to use the complement of the 
Kaplan-Meier survival function, because this will result in an 
overestimate of the incidence of the outcome of interest when 
competing risks are present. Instead, authors and analysts are 
encouraged to use the CIF. Our analyses illustrated the over-
estimates of the incidence of both cardiac death and noncar-
diac death that occurred when using the complement of the 
Kaplan-Meier survival curves to estimate incidence.
It is important to present results for all causes and for both 
cause-specific hazard functions and subdistribution hazard 
functions.17 Such a practice enables a more complete under-
standing not only of the effects of prognostic factors, but also 
Table 2. Hazard Ratios (and 95% Confidence Intervals) From Cause-Specific and Subdistribution Hazard 
Models for Cardiac and Noncardiac Death
Variable
Subdistribution Hazard Model Cause-Specific Hazard Model
Cardiac Death Noncardiac Death Cardiac Death Noncardiac Death
Age (per 10-y increase in age) 1.42 (1.38–1.46) 1.14 (1.10–1.17) 1.52 (1.48–1.56) 1.31 (1.27–1.35)
Respiratory rate (per 10 breaths/min increase) 1.12 (1.08–1.17) 1.07 (1.02–1.12) 1.18 (1.14–1.23) 1.15 (1.09–1.20)
Systolic blood pressure (per 10 mm Hg increase) 0.93 (0.92–0.94) 1.00 (0.99–1.01) 0.91 (0.90–0.92) 0.96 (0.95–0.97)
Urea nitrogen 1.02 (1.02–1.02) 1.01 (1.01–1.01) 1.03 (1.02–1.03) 1.02 (1.02–1.02)
Cancer 0.82 (0.75–0.89) 1.85 (1.71–2.01) 0.96 (0.89–1.04) 1.85 (1.71–2.00)
Cirrhosis 1.12 (0.82–1.54) 1.49 (1.10–2.02) 1.20 (0.89–1.62) 1.66 (1.24–2.22)
Cerebrovascular disease 1.26 (1.18–1.35) 1.01 (0.93–1.09) 1.30 (1.22–1.38) 1.13 (1.04–1.22)
Dementia 1.22 (1.11–1.33) 1.35 (1.22–1.50) 1.48 (1.37–1.60) 1.74 (1.59–1.92)
COPD 1.03 (0.97–1.1) 1.42 (1.33–1.52) 1.14 (1.08–1.21) 1.53 (1.44–1.64)
Low hemoglobin 0.87 (0.80–0.94) 1.49 (1.37–1.62) 0.95 (0.88–1.02) 1.50 (1.39–1.63)
Low sodium concentration 1.14 (1.07–1.22) 1.13 (1.05–1.22) 1.18 (1.11–1.25) 1.19 (1.11–1.28)
Each cell contains the hazard ratio and associated 95% confidence interval for the given covariate and the given hazard model. COPD 
indicates chronic obstructive pulmonary disease.
Table 3. Recommendations for Analyzing Competing Risk 
Survival Data
•   Cumulative incidence functions (CIFs) should be used to estimate the 
incidence of each of the different types of competing risks. Do not use the 
Kaplan-Meier estimate of the survival function for this purpose.
•   Researchers need to decide whether the research objective is on addressing 
etiologic questions or on estimating incidence or predicting prognosis.
•   Use the Fine-Gray subdistribution hazard model when the focus is on 
estimating incidence or predicting prognosis in the presence of competing 
risks.
•   Use the cause-specific hazard model when the focus is on addressing 
etiologic questions.
•   In some settings, both types of regression models should be estimated for 
each of the competing risks to permit a full understanding of the effect of 
covariates on the incidence and the rate of occurrence of each outcome.
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of the absolute risks of the different outcomes in the study 
sample. This is critical for decision makers, who may need 
to consider the risks of all events when making clinical deci-
sions. Someone with high risk of noncardiovascular mortality, 
but with a low risk of cardiovascular mortality may be treated 
differently than someone with low risk of noncardiovascu-
lar mortality and high risk of cardiovascular mortality. For 
instance, the latter patient may be an excellent candidate for 
early cardiovascular revascularization procedures, whereas 
the former patient may not be a suitable candidate for early 
revascularization.
There is a growing awareness of the impact of compet-
ing risks when developing prognostic models. Wolbers et al20 
compared the performance of a standard Cox survival model 
with that of a Fine-Gray model for predicting the incidence of 
coronary heart disease in older women. They found that the 
standard Cox model overestimated the 10-year risk of coro-
nary heart disease in comparison with the estimate from the 
Fine-Gray model. They classified 18% of subjects as being 
high risk based on the conventional Cox model, whereas 
they classified only 8% of subjects as being high risk when 
using the Fine-Gray model. They attributed this discrepancy 
to the increased risk of death attributable to competing risks 
in this elderly population. This example serves as a construc-
tive warning about the use of inappropriate statistical meth-
ods when estimating patient prognosis. We recommend that 
analysts use the Fine-Gray subdistribution hazard model when 
the focus is on estimating incidence or predicting prognosis in 
the presence of competing risks.
Given the availability of software, analyses of the cumula-
tive incidence function have become increasingly popular and 
widely reported in recent years. Biases may occur in naïvely 
estimating the cumulative incidence of the event of interest 
using the Kaplan-Meier estimator, as well as in naïvely esti-
mating the effects of covariates on the cumulative incidence 
function via a proportional hazards model for the cause-specific 
hazard function. The impact of incorrectly treating compet-
ing events as censoring events in these analyses has practical 
importance. In general, the greater the percentage of competing 
events, the greater the potential for bias in treating competing 
events as censoring events. Absolute percentages of competing 
events of >10% merit serious consideration, demanding care-
ful attention to the scientific objectives of the analysis and the 
appropriate choice of end point and method of analysis.
In our case study, we showed that a variable can have an 
effect on the incidence of an outcome that differs from its 
effect on the cause-specific hazard of the outcome. Such an 
observation has been made by Lau et al9
 previously. This high-
lights the need to examine the effect of covariates on both the 
incidences and the cause-specific hazard functions of all event 
types to develop a complete understanding of the relationships 
between the covariates and the different competing events. 
Competing risks entail events that preclude the occurrence of 
the outcome of interest. In some cases, further clarity may be 
required when deciding on what constitutes a competing risk 
before embarking on the analysis. For example, if a subject 
develops 1 form of heart disease, can he or she subsequently 
develop a second form of heart disease, or are the 2 conditions 
mutually exclusive, thus precluding the later second disease? 
Such clinical questions require resolution in the design phase 
before conducting the statistical analysis.
In summary, competing risks are prevalent in cardiovas-
cular research. We encourage analysts to take full advantage 
of the range of statistical methods for the analysis of survival 
data that have been developed in the statistical literature. 
Investigators need to be cognizant of the presence of com-
peting risks and their potential effect on statistical analyses. 
Researchers should select the appropriate method to address 
the study objectives and ensure that the analysis results are 
interpreted correctly.
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